GHRP-6 regulatory status
Current status of GHRP-6 in the United States: Not eligible for compounding. In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of GHRP-6?
- FDA and compounding
- Not FDA approved for any use. For 503A pharmacies, FDA lists GHRP-6 in Category 3, meaning it was nominated without enough support for FDA to evaluate it. It gets no protection under FDA's interim policy and is not on the 503A bulks list. For 503B outsourcing facilities, FDA placed GHRP-6 in Category 2 on September 29, 2023, citing immunogenicity risk from aggregation and impurities, effects on cortisol, and increased blood glucose from reduced insulin sensitivity. As of the last verification date no licensed pharmacy or outsourcing facility has a lawful basis to compound it.
- WADA
- WADA prohibited
- Access path
- No lawful United States access path identified on the last verified date: it is not FDA approved and is not on the 503A bulks list.
- Not available as an FDA approved product; FDA placed GHRP-6 in 503B Category 2 on September 29, 2023 and it has no 503A nomination or listing.
- Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.
Full GHRP-6 page: evidence, dosing in the literature, and sources
How has the status of GHRP-6 changed over time?
- WADA
WADA publishes the 2027 Prohibited List
WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.
- WADA
WADA 2026 Prohibited List takes effect
The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.
- WADA
WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times
The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 and its derivatives, including TB-500, and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.
- FDA
FDA places GHRP-2, GHRP-6, and ipamorelin in 503B Category 2
On September 29, 2023 FDA added growth hormone releasing peptide-2 (GHRP-2, for injectable and nasal routes), GHRP-6, and ipamorelin acetate to Category 2 under the 503B interim policy, citing immunogenicity risk from aggregation and peptide related impurities and, for GHRP-2, reports of serious adverse events. Outsourcing facilities may not compound a substance while it is in 503B Category 2. All three remain listed on the FDA page current as of April 22, 2026.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for GHRP-6 and the source of each dated event.
- [1]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
- [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
- [3]WADA Prohibited List, section S2 peptide hormones, growth factors, related substances and mimeticsWADA, 2026
- [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [5]WADA 2027 Prohibited ListWADA, 2026